

DAFTAR ISI

HALAMAN SAMPUL.....	i
LEMBAR PENGESAHAN.....	ii
PERNYATAAN KEASLIAN PENELITIAN.....	iii
KATA PENGANTAR.....	iv
ABSTRAK.....	viii
ABSTRACT.....	ix
DAFTAR ISI.....	x
DAFTAR TABEL	xiv
DAFTAR GAMBAR.....	xv
DAFTAR SINGKATAN.....	xvi
PENDAHULUAN.....	1
1.1 Latar Belakang.....	1
1.2 Rumusan Masalah.....	1
1.3 Tujuan Penelitian.....	3
1.3.1 Tujuan umum.....	3
1.3.2 Tujuan khusus.....	3
1.4 Manfaat Penelitian.....	4
1.4.1 Manfaat bagi ilmu pengetahuan.....	4
1.4.2 Manfaat bagi pelayanan kesehatan.....	4
TINJAUAN PUSTAKA.....	5
2.1 Definisi Leukemia Granulositik Kronik.....	5
2.2 Epidemiologi leukemia granulositik kronik.....	5
2.3 Patofisiologi leukemia granulositik kronik.....	8
2.4 Gejala klinis Leukemia Granulositik Kronik.....	13
2.5 Fase Leukemia Granulositik Kronik.....	13
2.6 Diagnosis Leukemia Granulositik Kronik.....	15
2.7 Terapi Leukemia granulositik kronik.....	17
2.7.1 Terapi pre TKI.....	18
2.7.2 Penghambat tyrosin kinase.....	20
2.7.2 Penghambat Sintesis Protein	25
2.7.3 Transplantasi Sel Punca Alogeneik.....	26

2.8 Pemantauan Respon Terapi	28
2.9 Faktor-faktor yang mempengaruhi kesintasan LGK.....	32
KERANGKA KONSEPTUAL DAN HIPOTESIS PENELITIAN.....	40
3.1 Kerangka Konseptual.....	40
3.2 Penjelasan Kerangka Konseptual.....	41
3.3 Hipotesis Penelitian	42
METODE PENELITIAN.....	43
4.1 Desain Penelitian.....	43
4.2 Tempat dan Waktu Penelitian.....	43
4.3 Jenis data.....	43
4.4 Populasi dan sampel penelitian.....	43
4.4.1 Populasi target.....	43
4.4.2 Populasi terjangkau.....	43
4.4.3 Sampel Penelitian.....	44
4.5 Besar Sampel.....	44
4.6 Cara Pengambilan Sampel Penelitian.....	44
4.7 Variabel Penelitian.....	44
4.8 Definisi Operasional.....	45
4.9 Protokol Penelitian.....	48
4.10 Analisis Data.....	49
4.11 Keterbatasan Penelitian.....	49
HASIL ANALISIS DATA.....	50
5.1 Karakteristik Umum Pasien Subjek Penelitian.....	50
5.2 Profil Pencapaian Respons Hematologi Komplet 3 Bulan.....	51
5.3 Kesintasan Kumulatif Pasien LGK Fase Kronik yang Mendapatkan Imatinib.....	52
5.4 Kesintasan Subyek Penelitian Berdasarkan Respons Hematologi Komplet	57
PEMBAHASAN.....	58
6.1 Karakteristik Umum Pasien Subjek Penelitian.....	58
6.2 Pencapaian Respons hematologi 3 bulan setelah pemberian imatinib	61

6.3	Kesintasan Kumulatif Pasien LGK.....	62
6.4	Analisis Kesintasan Rsepons Hematologi Komplet 3 bulan.....	63
6.5	Keterbatasan Penelitian.....	66
KESIMPULAN DAN SARAN.....		69
7.1	Kesimpulan.....	69
7.2	Saran.....	70
DAFTAR PUSTAKA		71
LAMPIRAN		76

DAFTAR TABEL

Tabel 2.1 Kriteria fase akselerasi	19
Tabel 2.2 Kriteria fase krisis blastik.....	19
Tabel 2.3 Respon pemantauan terapi LGK	19
Tabel 5.1 Karakteristik subjek penelitian pre pemberian imatinib	40
Tabel 5.2 Karakteristik Subjek Penelitian Paska Pemberian Imatinib selama 3 bulan.....	47
Tabel 5.3 Analisis <i>cox regression</i> respon hematologi dengan kesintasan pasien LGK	48

DAFTAR GAMBAR

Gambar 3.1 Kerangka konseptual.....	29
Gambar 5.1 Diagram Pencapaian Respon Hematologi 3 Bulan.....	41
Gambar 5.2 Kurva Kaplan-meier Kumulatif Kesintasan pasien LGK.....	41
Gambar 5.3 Kurva Kaplan-meier respons hematologi komplet.....	42

DAFTAR SINGKATAN

ABL	: <i>abelson murine leukemia</i>
ALL	: <i>acute lymphoblastic leukemia</i>
AML	: <i>acute myeloid leukemia</i>
APC	: <i>antigen-presenting cell</i>
ATP	: <i>adenosine triphosphate</i>
BAD	: <i>BCL2 associated agonist of cell death</i>
BCR	: <i>breakpoint cluster region</i>
CCyR	: <i>Complete Cytogenetic response</i>
CHR	: <i>Complete hematologic response</i>
CMML	: <i>chronic myelomonocytic leukemia</i>
CyR	: <i>Cytogenetic response</i>
DMR	: <i>Deep Molecular Remission</i>
ELN	: <i>European Leukemia Net</i>
EFS	: <i>event free survival</i>
ESMO	: <i>European Society for Medical Oncology</i>
FDA	: <i>Food and Drug Administration</i>
FOXO	: <i>forkhead O transcription factors</i>
FISH	: <i>Fluorescent in situ hybridization</i>
GDP	: <i>Guanosine diphosphat</i>
GRB2	: <i>growth factor receptor-bound protein 2</i>
GTP	: <i>Guanosine-5'-triphosphate</i>
HR	: <i>hazard ratio</i>
IL	: <i>interleukin</i>
INF- α	: <i>interferon alfa</i>
IRIS	: <i>International Randomized Study of Interferon and STI571</i>
JAK	: <i>Janus-Activated kinase</i>
LAP	: <i>Leucocyte Alkalin phosphatase</i>
LGK	: <i>Leukemia granulositik kronik</i>
LLK	: <i>leukemia limfositik kronik</i>
M-bcr	: <i>Major break cluster</i>
m-bcr	: <i>Minor break cluster</i>

MAPK	: <i>Ras-Mitogen-Activated Protein kinase</i>
MCR	: <i>major cytogenetic response</i>
micro-bcr	: <i>micro break cluster</i>
MMR	: <i>Major molecular response</i>
NF- κ B	: <i>nuclear factor kappa-light-chain-enhancer of activated B cells</i>
OR	: <i>odd ratio</i>
OS	: <i>overall survival</i>
PCR	: <i>Polymerase chain reaction</i>
PCyR	: <i>Partial Cytogenetic response</i>
PD-GFR	: <i>Platelet derived growth factor receptor</i>
PFS	: <i>progression free survival</i>
PH	: <i>pleckstrin-homology</i>
PI3K	: <i>phosphoinositide 3-kinase</i>
RHO-GEF	: <i>Rho guanidine nucleotide exchange factors</i>
RES	: <i>reticuloendothelial system</i>
S6K	: <i>S6 kinase</i>
SOS	: <i>Son of Sevenless</i>
STAT	: <i>signal transducers and activators of transcription</i>
TKI	: <i>tyrosine kinase inhibitor</i>
VOD	: <i>Venouse Occlusive Disease</i>